多重用药与类风湿关节炎治疗反应及严重不良事件相关:BSRBR-RA登记研究结果
基于英国风湿病学会生物制剂登记(BSRBR-RA)的前瞻性观察队列,纳入22 005例患者,评估多重用药与RA治疗反应及严重不良事件(SAE)的关系。每增加一种药物,12个月EULAR良好反应 odds 降低(校正OR 0.97,95%CI 0.95-0.98,P<0.001),SAE风险升高(校正HR 1.06,95%CI 1.05-1.07,P<0.001)。多重用药是RA临床结局的简单有效预测指标。
要点
- 每增加一种药物,12个月EULAR良好反应校正OR为0.97(95%CI 0.95-0.98,P<0.001)。
- 每增加一种药物,SAE风险校正HR为1.06(95%CI 1.05-1.07,P<0.001)。
- 多重用药模型对治疗反应的预测AUC显著优于Rheumatic Disease Comorbidity Index。
核心结论
- 多重用药是RA患者临床结局的简单但有价值的预测指标,支持用药计数作为流行病学分析的有效指标。
研究设计与样本
- BSRBR-RA为前瞻性观察队列,纳入生物制剂起始者和DMARD对照臂,共分析22 005例患者,其中83%起始生物制剂。
- 采用logistic回归计算12个月生物制剂治疗后EULAR良好反应的odds,采用Cox比例风险模型识别SAE风险。
- 通过ROC和Harrell C统计量比较多重用药模型与Rheumatic Disease Comorbidity Index的预测效用。
主要发现
- 每增加一种药物,EULAR良好反应odds未校正降低8%(OR 0.92,95%CI 0.91-0.93,P<0.001),校正后降低3%(aOR 0.97,95%CI 0.95-0.98,P<0.001)。
- 多重用药模型对治疗反应的ROC曲线下面积显著大于Rheumatic Disease Comorbidity Index。
- 7 286例患者共报告12 547例次SAE;每增加一种药物,SAE风险未校正增加13%(HR 1.13,95%CI 1.12-1.13,P<0.001),校正后增加6%(aHR 1.06,95%CI 1.05-1.07,P<0.001)。
- 多重用药模型与Rheumatic Disease Comorbidity Index对SAE的预测值相当。
关键数值与推荐
- EULAR良好反应:每增加一种药物校正OR 0.97(95%CI 0.95-0.98,P<0.001)。
- SAE:每增加一种药物校正HR 1.06(95%CI 1.05-1.07,P<0.001)。
临床怎么用
- 在RA患者中可用简单用药计数辅助识别治疗反应较差和SAE风险较高者。
- 多重用药计数可作为流行病学分析中合并症负担的简便替代指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether polypharmacy is associated with treatment response and serious adverse events (SAEs) in patients with RA using data from the British Society for Rheumatology Biologics Register (BSRBR-RA). METHODS: The BSRBR-RA is a prospective observational cohort study of biologic therapy starters and a DMARD comparator arm. A logistic regression model was used to calculate the odds of a EULAR 'good response' after 12 months of biologic therapy by medication count. Cox proportional hazards models were used to identify risk of SAEs. The utility of the models were compared with the Rheumatic Disease Comorbidity Index using Receiver Operator Characteristic and Harrell's C statistic. RESULTS: The analysis included 22 005 patients, of which 83% were initiated on biologics. Each additional medication reduced the odds of a EULAR good response by 8% [odds ratios 0.92 (95% CI 0.91, 0.93) P < 0.001] and 3% in the adjusted model [adjusted odds ratios 0.97 (95% CI 0.95, 0.98) P < 0.001]. The Receiver Operator Characteristic demonstrated significantly greater areas under the curve with the polypharmacy model than the Rheumatic Disease Comorbidity Index. There were 12 547 SAEs reported in 7286 patients. Each additional medication equated to a 13% increased risk of an SAE [hazard ratio 1.13 (95% CI 1.12, 1.13) P < 0.001] and 6% in the adjusted model [adjusted hazard ratio 1.06 (95% CI 1.05, 1.07) P < 0.001]. Predictive values for SAEs were comparable between the polypharmacy and Rheumatic Disease Comorbidity Index model. CONCLUSION: Polypharmacy is a simple but valuable predictor of clinical outcomes in patients with RA. This study supports medication count as a valid measure for use in epidemiologic analyses.
引用
- Bechman K, Clarke BD, Rutherford AI, et al. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2019. PMID: 30982886. doi:10.1093/rheumatology/kez037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。